Lilly Weight-Loss Drug Data Spurs Selloff in Sleep Apnea Stocks BloombergWhy a Pair of Eli Lilly Clinical Trials Sent ResMed Stock Tumbling InvestopediaLilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution | Eli Lilly and Company Investors | Eli Lilly and CompanyAmid duel with Novo's Wegovy, Lilly's Zepbound homes in on potential FDA sleep apnea nod FiercePharma